Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Study Overview
=================
Brief Summary
-----------------
This is a Phase 2 study to evaluate posoleucel (ALVR105, formerly Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6 and JC virus.

Detailed Description
-----------------
This is a Phase 2/3, multicenter, randomized, double-blind, placebo controlled trial comparing posoleucel to placebo for the prevention of infection or disease due to AdV, BKV, CMV, EBV, HHV-6, or JCV in high-risk adult and pediatric patients after allogeneic HCT. There are 2 parts to the study, an open label Phase 2 cohort described in this posting, and a randomized, placebo controlled Phase 3 cohort described in NCT05305040. In the Phase 2 part, 25 to 35 eligible allogeneic HCT recipients will be enrolled and will receive 7 doses of posoleucel over 12 weeks, followed by a 14 week follow-up period.

Official Title
-----------------
Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV-6, and JCV Infection and/or Disease, in High-Risk Patients After Allogeneic Hematopoietic Cell Transplant

Conditions
-----------------
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection

Intervention / Treatment
-----------------
* Biological: Posoleucel (ALVR105)


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria ≥1 year of age at the day of screening visit. Either no evidence of viral infection or viremia, or asymptomatic, viral infection with 3 or fewer viruses of interest at time of screening Within 15 and 42 days of receiving a first allogeneic HCT and have demonstrated clinical engraftment Meet one or more of the following criteria at the time of randomization: Related (sibling) donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B or -DR Haploidentical donor Unrelated donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B, -C, or -DR Use of umbilical cord blood as stem cell source Ex vivo graft manipulation resulting in T cell depletion Lymphocyte Count <180/mm3 and/or cluster of differentiation 4 (CD4) Count <50/mm3 Key Exclusion Criteria: History of AdV, BKV, CMV, EBV, HHV-6, and/or JCV end-organ disease within 6 months prior to randomization Evidence of active Grade >2 acute GVHD Presence of non-minor uncontrolled or progressive bacterial, viral or fungal infections Known history or current (suspected) diagnosis of CRS requiring treatment associated with the administration of peptides, proteins, and/or antibodies Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose >0.5 mg/kg/day) within 24 hours prior to dosing Relapse of primary malignancy other than minimal residual disease Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Posoleucel (ALVR105)<br>Administered as 2-4 milliliter infusion | Biological: Posoleucel (ALVR105)<br>* Administered as 2-4 milliliter infusion<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of clinically significant infections or episodes of end-organ disease |  | Through Week 14 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of clinically significant infections or episodes of end-organ disease |  | Through Week 26 | 
| Number of clinically significant infections or episodes of end-organ disease due to each virus |  | Through Weeks 14 and 26 | 
| Mean area under the curve (AUC) viral load |  | Through Weeks 14 and 26 | 
| Incidence of Adverse Events |  | Through Week 26 | 
| Rates of Overall and Non-Relapse Mortality |  | Through Week 26 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Allogeneic Hematopoietic Cell Transplant, Posoleucel, ALVR105, Viralym-M